Preoperative Serum IL-6 Levels: Clinical Importance in Gastric Carcinoma with Lymph Node Metastasis

Özgür Kemik¹, Aziz Sümer¹, Ahu Sarbay Kemik², A Cumhur Dülger³, İsmail Hasırcı¹, Mine Adaş⁴, Sevim Purisa⁵, Sefa Tüzün⁶

Yuzuncu Yıl University Medical Faculty, Department of General Surgery¹ and Gastroenterology³, Van
Istanbul University, Cerrahpasa Medical Faculty, Departments of Biochemistry² and Biostatistic⁵, İstanbul
Okmeydanı Training Hospital, Department of Endocrinology, İstanbul
Haseki Training Hospital, II. General Surgery Department, İstanbul
Eur J Gen Med 2010;7(4):410-413
Received: 10.02.2010
Accepted: 08.04.2010

Correspondence: Dr. Özgür Kemik
Department of General Surgery, Yuzuncu Yıl University Medical Faculty, Van
Phone: 0 532 371 4255
E-mail address: ozgurkemik@hotmail.com

European Journal of General Medicine

ABSTRACT

Aim: The interleukin-6 (IL-6) pathway is one of the mechanisms that link inflammation and angiogenesis. The purpose of this study was to investigate the preoperative serum levels of IL-6 in gastric carcinoma with lymph node metastasis, and to correlate them with disease status.

Method: A total of 100 patients who underwent gastrectomy were enrolled in this study. Serum levels of IL-6 were assessed enzyme linked immunosorbent assay (ELISA). Histological findings included tumor size, depth of tumor invasion, lymph node (LN) metastasis, and TNM stage.

Result: Increases in cancer invasion and staging are generally associated with increases in preoperative serum IL-6 levels. IL-6 levels were correlated with invasion depth (p<0.001), LN metastasis (p<0.001), and TNM stage. The presence of peritoneal seeding metastasis is associated with IL-6 levels (p<0.001).

Conclusion: Preoperative serum IL-6 levels might be markers of tumor invasion, LN metastasis, and TNM stage. These results suggest that IL-6 levels are potential molecular markers that predict lymphatic involvement in gastric carcinoma.

Key words: IL-6, lymph node, metastasis, gastric carcinoma.
INTRODUCTION

Gastric cancer is one of the leading causes of death in the world. Metastasis to the regional lymph node is an indicator of tumor progression as well as an important prognostic factor in gastric cancer. Recent evidence suggests that tumor lymphangiogenesis promotes lymphatic metastasis (1-4). However, little is known about the mechanism of lymphangiogenesis in gastric carcinoma. Interleukin-6 (IL-6) is a multi-poietic cytokine that induces the growth and differentiation of immune cells, the expression of other cytokines, and acute-phase protein synthesis. IL-6 also marks various effects on cancer cells (5, 6).

In cancer, IL-6 is mostly known to be involved in crew defense mechanisms. IL-6 binds to the IL-6 receptor, activates the Janus kinase (JAK), and subsequently phosphorylates the signal transducers and activators of transcription (STAT). Suppressor of cytokine signaling-1 (SOCS-1) is one of the STAT-activated genes, which is upregulated by IL-6 and is involved in the down-regulation of the JAK/STAT pathway (7-9). In many cancer types, recent studies have demonstrated that the hypermethylation of SOCS-1 is not controlled by the JAK/STAT pathway, and IL-6 cannot perform a role in cancer defense; on the contrary, it is involved in cancer development and angiogenesis (7, 10). In the development of cancer, angiogenesis is a definite and elemental process. IL-6 is associated with angiogenesis by virtue of its capability to induce the mRNA of vascular endothelial growth factor (VEGF), which is typically a direct angiogen (5). Additionally, IL-6 activates the Rho protein, which is associated with cell-cell adhesion and invasion in malignancy (11).

The largely purpose of this study was to determine the relationship between serum IL-6 and lymphangiogenesis and prognosis in gastric cancer patients.

MATERIALS AND METHODS

This study enrolled 100 patients who underwent surgical resection for gastric adenocarcinoma at Haseki Education and Research Hospital between December 2007 and October 2009. Well-documented clinical data were collected from all patients. All patients provided informed consent, and the hospital review board approved the study. Venous blood sampling was enrolled within 7 days before the patients underwent operations. The blood collected for IL-6 serum level assessments was collected in plain tubes, and the levels of serum IL-6 were measured using commercially available enzyme-linked immunosorbent assay (ELISA) (Quantikine human IL-6 Immunassay, R&D Systems, USA). The blood samples were centrifuged for 10 min at 3000 r/min at -4°C. The serum was subsequently removed and stored at -80°C until biochemical analysis. Serum levels of IL-6 were measured using commercially available enzyme-linked immunosorbent assay (ELISA) (Quantikine human IL-6 Immunassay, R&D Systems, USA). The blood samples were centrifuged for 10 min at 3000 r/min at -4°C. The serum was subsequently removed and stored at -80°C until biochemical analysis. Serum levels of IL-6 were expressed as the means ± SD. A p value of <0.05 was considered to be statistically significant. The Pearson chi-square test was performed to determine the correlation between IL-6 levels and various clinicopathological factors.

RESULTS

The patients were classified by their pathologic characteristics, including tumor size, depth of tumor invasion, status of lymph node metastasis, TNM staging, and peritoneal metastasis. The patients consisted of 58 men and 42 women, with a median age of 57 years (range, 35-78 years). The characteristics data of the study population are shown in Table 1. 51 patients evidence tumor sizes of ≥ 5 cm. The depth of tumor invasion was pT1 in 20 patients, pT2 in 34, pT3 in 31, and pT4 in 15. LN me-
tastasis was detected in 81 patients. The postoperative stages of the patients were I, II, III, and IV in 27, 25, 30, and 18 patients, respectively. Ten patients in this study had peritoneal metastasis.

We noted that IL-6 levels were significantly correlated with IL-6 levels, and tumor size with higher IL-6 levels was detected in tumors sized ≥ 5cm. In addition, with increasing degrees of tumor invasion, the median levels of IL-6 evidenced an affinity to increase, and this difference in IL-6 levels was found to be statistically significant. In cases of LN metastasis, we also noted a significant difference between the serum level of IL-6 increased with the stage of the cancer, and this difference was statistically significant. In addition, serum IL-6 levels were significantly higher in patients with peritoneal metastasis than in those without peritoneal seeding.

**DISCUSSION**

In this study, the serum levels of IL-6 evidenced statistically significant differences in tumor size, tumor invasion depth, and LN metastasis. In the TNM stage, as the stage of the disease increased, serum IL-6 levels were significantly higher. In addition, the median levels of IL-6 were significantly higher in the patients with peritoneal seeding than in those without peritoneal seeding.

IL-6 was confirmed as independent factors. In some papers, it has been reported that IL-6 was an active prognostic indicator in stages II and III (12). There have been a great many studies conducted concerning the values and functions of IL-6 in malignancy. These studies have present that IL-6 levels were higher in malignancies than in non-malignancies, and increased with enhancing tumor size and depth (13,14). We determined a statistically significant relationship between IL-6 levels and LN metastasis. However, some studies have reported no relationship between IL-6 levels and LN metastasis (15). LN metastasis was shown to be affected by independent

| Variables                      | n   | IL-6 (pg/ml) | p value |
|-------------------------------|-----|--------------|---------|
| **Total**                     | 100 | 7.01±2.81    |         |
| **Sex**                       |     |              |         |
| Male                          | 58  | 7.43±1.92    | 0.312   |
| Female                        | 42  | 5.91±1.56    |         |
| **Age**                       |     |              |         |
| <60                           | 49  | 6.78±2.92    | 0.019   |
| ≥60                           | 51  | 7.24±3.18    |         |
| **Tumor size**                |     |              |         |
| <5cm                          | 49  | 5.89±3.03    | 0.037   |
| ≥5cm                          | 51  | 9.27±2.39    |         |
| **Tumor depth**               |     |              |         |
| pT1                           | 20  | 5.43±1.29    |         |
| pT2                           | 34  | 5.99±1.56    |         |
| pT3                           | 31  | 7.82±2.34    |         |
| pT4                           | 15  | 9.43±2.58    | 0.001   |
| **LN metastasis**             |     |              |         |
| N0                            | 11  | 5.97±1.56    |         |
| N1                            | 29  | 6.41±1.68    |         |
| N2                            | 30  | 7.38±2.11    |         |
| N3                            | 10  | 9.47±1.28    | 0.001   |
| **Peritoneal metastasis**     |     |              |         |
| Met (-)                       | 90  | 6.17±3.05    |         |
| Met (+)                       | 10  | 9.27±2.39    | 0.001   |
| **TNM stage**                 |     |              |         |
| I                             | 27  | 7.36±3.12    |         |
| II                            | 25  | 7.99±2.63    |         |
| III                           | 30  | 8.78±2.91    |         |
| IV                            | 18  | 9.54±3.05    | 0.001   |
Preoperative serum IL-6 levels in gastric carcinoma

Preoperative serum IL-6 levels in gastric carcinoma predictors in cases of advanced cancers. Many studies have also showed that IL-6 levels enhanced in cases of distant metastasis, notably hepatic metastasis (13,14). This result has been imputed to a crew of mechanisms, including the autocrine and paracrine pathways. With regard to the autocrine pathway, IL-6 activated the production of IL-6 by tumor cells with the IL-6 receptor. With the regard to the paracrine pathway, IL-6 stimulated stromal cells promoted the secretion of tumor growth and adhesion molecules containing (6,13,16). Lymphangiogenesis is one of the fundamental mechanisms which contribute to the progression of cancer. Because high IL-6 levels that block the some signaling pathway might block lymphangiogenous metastasis, IL-6 has been widely analyzed as a possible target for cancer treatment.

Preoperative serum IL-6 levels were related to cancer stage and might be markers of tumor invasion, LN metastasis and TNM stage. Particularly high IL-6 levels were presented as an important factor of lymphangiogenesis.

REFERENCES

1. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001;7:186-91.
2. Mandriota SJ, Jussila L, Jeltsch M, et al. vascular endothelial growth factor-C mediated lymphangiogenesis promotes tumor metastasis. EMBO J 2001;20:672-82.
3. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-8.
4. Choi JH, Oh YH, Park YW, Balk HK, Lee YY, Kim S. Correlation of VEGF-D expression and VEGFR3-positive vessel density with lymph node metastasis in gastric carcinoma. J Korean Med Sci 2008 23(4):592-7.
5. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. IL-6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271(2):736-41.
6. Thong-Ngam D, Tangkijvannich P, Lerknimitr R, Mahachi V, Theamboonlers A, Poorawan Y. Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterology 2006;12(28):4473-7.
7. To KF, Chan MW, Leung WK, et al. Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line. Br J Cancer 2004;91(7):1335-41.
8. Watanabe S, Mu W, Kahn A, et al. Role of JAK/STAT pathway in IL-6-induced activation of vascular endothelial smooth muscle cells. Am J Nephrol 2004;24(4):387-92.
9. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004;117 (Pt 8):1281-3.
10. Heinrich PC, Behrmann I, Haan S, et al. Principles of IL-6-type cytokine signaling and its regulation. Biochem J 2003;374(Pt 1):1-20.
11. Lin MT, Lin BR, Chang CC, et al. IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/Rock signaling pathway. Int J Cancer 2007;120(12):2600-8.
12. Liao WC, Lin JT, Wu CY, et al. Serum IL-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res 2008;14(2):428-34.
13. Ashizawa T, Okada R, Suzuki Y, et al. Clinical significance of IL-6 in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2008;11(2):124-31.
14. Chung YC, Chang YF. Serum IL-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003;83(4):222-6.
15. Huang SP, Wu MS, Wang HP, Yang CS, Kuo ML, Lin JT. Correlation between serum levels of IL-6 and VEGf in gastric carcinoma. J Gastroenterol Hepatol 2002;17(11):1165-9.
16. Nikiteas NI, Tzanakis N, Gazouli M, et al. Serum IL-6, TNF-alpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005;11(11):1639-43.